{"id":"NCT01063855","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","briefTitle":"Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction","officialTitle":"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2011-08","completion":"2011-09","firstPosted":"2010-02-05","resultsPosted":"2012-11-05","lastUpdate":"2013-01-24"},"enrollment":495,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Erectile Dysfunction","Sexual Dysfunction"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Dapoxetine","otherNames":[]},{"type":"DRUG","name":"PDE5I (phosphodiesterase-5 inhibitor)","otherNames":[]}],"arms":[{"label":"Dapoxetine + PDE5I","type":"EXPERIMENTAL"},{"label":"Placebo + PDE5I","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of dapoxetine compared to placebo in men with premature ejaculation and erectile dysfunction who are currently being treated with a phosphodiesterase-5 inhibitor (ie, sildenafil, vardenafil, or tadalafil) for erectile dysfunction.","primaryOutcome":{"measure":"The Average Intravaginal Ejaculatory Latency Time (IELT) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"PDE5I + Placebo (Baseline)","deltaMin":1.1,"sd":0.53},{"arm":"PDE5I + Placebo (Week 12)","deltaMin":3.4,"sd":3.54},{"arm":"PDE5I + Dapoxetine (Baseline)","deltaMin":1.1,"sd":0.55},{"arm":"PDE5I + Dapoxetine (Week 12)","deltaMin":5.2,"sd":5.78}],"pValues":[{"comp":"OG000 vs OG001 vs OG002 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":69,"countries":["United States","Argentina","Australia","Belgium","Canada","France","Malaysia","Mexico","Poland","Russia","South Korea","Taiwan","United Kingdom"]},"refs":{"pmids":["23845016"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":245},"commonTop":["Nausea","Headache","Diarrhoea","Dizziness","Nasopharyngitis"]}}